4 BioPharma Movers That Cannot Be Ignored
These biotech companies 24/7 Wall St. has picked stood out from the rest with big moves over the course of last week.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 225
Clovis Gears Up for NDA Discussion in April
Clovis Oncology traded down on Friday after the company said the FDA scheduled the New Drug Application for rociletinib for discussion by the Oncologic Drugs Advisory Committee on April 12.
Incyte Underwhelms With Earnings
Incyte reported better-than-expectged fourth-quarter financial results after the markets closed on Wednesday.
CTI BioPharma Stumbles Over Full Clinical Hold
CTI BioPharma has practically become a penny stock overnight following an update from its Investigational New Drug (IND) application for pacritinib.
Proteostasis Therapeutics Closes in on IPO
Proteostasis Therapeutics expects to price less than 4 million shares in the range of $12 to $14 apiece in an initial public offering valued up to around $62 million.
Humana Outlook Raises Share Price After Earnings
Humana reported mixed fourth-quarter and full-year 2015 results before markets opened Wednesday morning.
Short Sellers Increase Bets in Major Pharma
The January 29 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
Major Biotech Short Interest Continues to Be Mixed
The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of the selected biotech stocks.
Adaptimmune Receives Breakthrough Designation From FDA
Adaptimmune Therapeutics has announced that the FDA granted a Breakthrough Therapy designation for the company's affinity enhanced T-cell therapy.
Cerus Announces New Partnership With Red Cross
Cerus led the bulls in Tuesday’s trading session on news of a new partnership with one of the biggest charities in the world.
Why Merrill Lynch Sees Big Upside in Pfizer (and Even More With Allergan)
Merrill Lynch has decided to add Pfizer as its new top pick for 2016. The firm reiterated a Buy rating with a $39 price target.
Regeneron Falls on Missed Earnings
Regeneron Pharmaceuticals reported disappointing fourth-quarter financial results before the markets opened on Tuesday.
What to Expect From Centene Earnings
Health insurance provider Centene is scheduled to report fourth-quarter earnings on Tuesday morning before markets open.
Is BioCryst Reaching Crush Depth?
BioCryst Pharmaceuticals shares were crushed after it announced results from OPuS-2 for the treatment of hereditary angioedema attacks.
4 Big Dividend Pharmaceutical Stocks to Buy That Are Very Cheap Now
If you ever want to look for value in a sector in the stock market, then when you see Congress calling in some of the top companies to scold them for political purposes, you…